Program Description
Idiopathic pulmonary
fibrosis (IPF) is a life-limiting interstitial lung disease characterized by
the progressive formation of scar tissue in the lungs, leading to irreversible
loss of lung function. With a median survival of just 3 to 5 years after diagnosis,
IPF imposes a significant clinical and economic burden on patients and the
health care system. Several challenges from delayed diagnosis to
underutilization of guideline-recommended antifibrotics and issues with
medication adherence and tolerability impact care for patients with IPF. This
didactic panel discussion, featuring patient case scenarios and a patient
perspective interview, will examine the pathophysiology and clinical burden of
IPF, including its impact on quality of life and health care resources. Expert
panelists will examine the current treatment landscape and review emerging
therapeutic agents. The program will also emphasize the critical role of the
specialty pharmacist in optimizing care, focusing on patient counseling,
strategies for enhancing adherence, and overcoming common barriers and
challenges to ensure patients receive timely and appropriate treatment.
Target Audience: Specialty Pharmacist
Type of Activity: Application
Release date: December
5, 2025
Expiration date: December
5, 2026
Learner
level: Foundational,
Intermediate
Time to complete activity: 1.5 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology and clinical burden of idiopathic pulmonary fibrosis (IPF)
- Compare currently approved pharmacologic therapies for IPF and their mechanisms of action
- Identify emerging therapeutic agents in the IPF pipeline and their potential impact on clinical care
- Explore the pharmacist’s evolving role in managing patients with IPF, including access, adherence, and patient education
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here